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Purpose: Retinoblastoma (RB), the most common intraocular tumor occurring in infancy and early childhood, is most
often related to mutations in the RB1 gene. In this study, we screened the RB1 germline mutations in 41 unrelated Moroccan
patients with retinoblastoma, 25 heritable cases, and 16 sporadic unilateral cases.
Methods: After complete ophthalmic examinations were performed and consent obtained, DNA was extracted from
peripheral blood, and screening of RB1 mutations was performed with PCR direct sequencing of the promoter and the 27
coding exons of the RB1 gene.
Results: We identified ten germline mutations in 10/41 (24.39%) unrelated patients, among which three had not been
previously reported. The mutation detection rate was 40% (10/25) in the heritable cases and 0% (0/16) in the sporadic
unilateral cases. Of these mutations, six were nonsense, and three were frameshifts, all associated with severe phenotypes
resulting in bilateral and multifocal tumors. One splice site mutation was found in a familial case associated with a low
expressivity phenotype resulting in unilateral and unifocal tumors. Moreover, eight intronic variants were identified, three
of which were novel.
Conclusions: This first report of RB1 gene screening in Moroccan patients with retinoblastoma shows a comparable
mutational spectrum to those reported previously, which has evident importance for managing patients with retinoblastoma
and their families.
Retinoblastoma (RB, OMIM 180200], the most frequent
childhood intraocular tumor, is caused by mutations in the
RB1 gene. The tumor arising from embryonic retinal cells
occurs in 1:15,000 to 1:20,000 live births, with no bias in the
sex ratio [1]. In Morocco, the incidence of RB was estimated
at  about  50  new  cases  annually  [2].  Worldwide,
approximately  40%  of  RB  cases  are  heritable  cases.  The
predisposition to develop RB is inherited as an autosomal
dominant trait, but mutations in both alleles are necessary to
cause  the  disease  [3].  Individuals  carrying  a  germline
mutation are predisposed within the first 2 years of life to
multifocal bilateral tumors, and later in adulthood to bone and
connective tissue tumors [4,5]. The germline mutations are
associated with predisposition with a high penetrance (90%
or more) to RB and most often inherited from an affected
parent  (hereditary  familial  RB)  or  acquired  during
gametogenesis  or  gestation  (hereditary  de  novo)  [3,6].
Nevertheless, low penetrance and variable expressivity of the
disease  have  been  described  in  some  families  presenting
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bilateral  or  unilateral  RB,  benign  retinoma,  or  unaffected
carriers [7–9]. Non-hereditary RB, representing 60% of cases,
is unilateral and does not induce increased lifetime risk of non-
ocular tumors. In these cases, mutations in both RB1 alleles
take place in a single retinal cell that will develop to form the
tumor [1,10,11].
Mutations in the RB1 gene are highly heterogeneous and
scattered in the promoter and the 27 coding exons. Previous
reports  described  a  wide-ranging  mutation  detection  rate,
from 5.5% to 94.8%, according to the patient selection criteria
(unilateral, bilateral, familial, and/or sporadic cases) and the
screening  techniques  [12–19].  Single  base  substitutions
represent  the  most  frequent  mutations,  and  among  them,
nonsense mutations predominate (Retinoblastoma genetics).
The  existence  of  genetic  modifiers  in  RB  was  recently
identified  in  the  MDM2  gene  as  a  modulator  of  disease
severity [20,21].
To  identify  the  spectrum  and  the  effect  of  germline
mutations and to provide accurate genetic counseling, we
performed a genetic analysis of the RB1 gene in a Moroccan
retinoblastoma cohort.
METHODS
Patients: This study included 41 unrelated cases of RB with
different clinical presentations, recruited between November
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35412009 and August 2010. Of these, 25 had heritable disease with
23  sporadic  bilateral  and  two  familial  cases,  and  16  had
sporadic unilateral RB. The patients, 20 girls and 21 boys (sex
ratio of 0.95) with age at diagnosis ranging from 2 to 36
months,  were  examined  and  treated  at  the  pediatric
ophthalmology department of the 20 Aout Hospital, CHU of
Casablanca, Morocco. Clinical features (tumor laterality, type
and number of tumor foci) were diagnosed for each patient
and  associated  with  a  questionnaire.  Blood  samples  were
obtained  in  standard  EDTA  blood  collection  tubes  from
patients  and  available  relatives  after  individual  written
consent for genetic analysis was obtained, in accordance with
the  Declaration  of  Helsinki.  The  samples  were  stored  at
−20 °C until nucleic acid extraction.
Molecular  analysis:  DNA  was  extracted  from  peripheral
blood using the phenol/chloroform method [22]. Screening of
germline mutations in the RB1 gene was performed with PCR-
directed sequencing of the promoter and the 27 coding exons,
and  their  flanking  intronic  regions,  using  the  primers
described  by  Abouzeid  et  al.  [8].  PCR  reactions  were
performed in a thermal cycler (ABI 2700), in a total volume
of 15 µl containing 25–50 ng of genomic DNA, 3 picomoles
of each primer, and 7.5 µl of master mix 2× (AmpliTaq Gold
360  Master  Mix;  Applied  Biosystems,  Foster  City,  CA).
Reactions were performed for 35 cycles of 94 °C for 1 min,
annealing at the specific temperature for 1 min, 72 °C for 1
min, and a final extension step at 72 °C for 7 min. After the
unincorporated deoxynucleoside triphosphates and primers
were  removed  using  Exonuclease  I  and  shrimp  alkaline
phosphatase  (ExoSAP-IT  PCR  Purification  Kit,  GE
Healthcare, UK), the PCR products were directly sequenced
using the ABI BigDye Terminator v 3.1 Sequencing Standard
Kit (Applied Biosystems, Foster City, CA) and run on an ABI
3130 Genetic Analyzer. The sequence data were analyzed by
comparison  to  the  consensus  sequence  of  the  RB1  gene
(GenBank  L11910.1)  using  ABI  SeqScape  v2.5  software.
Additional  information  about  mutations  and  variants  was
obtained from the RB1 gene database.
RESULTS
Out of the 41 RB patients tested for RB1 germline mutations,
we found 25 (61%) heritable cases with 23 sporadic bilateral
and two familial cases and 16 (39%) nonhereditary cases,
sporadic unilateral. The mean age at diagnosis was 10.54
months for bilateral patients and 17 months for unilateral
patients. In total, we identified ten causative RB1 mutations
in ten out of 41 patients (global mutation rate of 24.39%; Table
1). Among these patients, nine had sporadic bilateral RB, and
one had familial unilateral RB. Therefore, the detection rate
of RB1 mutations was 40% (10/25) in heritable cases and 0%
(0/16) in sporadic unilateral cases. Three mutations (30%)
were novel, and seven (70%) had been previously reported
(RB1  gene  database).  Seven  mutations  were  single-base
substitutions  leading  to  six  nonsense  (p.Arg358X,
p.Arg455X,  p.Arg552X,  p.Tyr651X,  p.  Lys652X,
p.Arg787X) amino acid changes and one splice site mutation
(c.719–2A>G) in intron 7. The three other mutations were
small deletions of one or two base pairs causing a frameshift
and  premature  termination  (p.Ile124ArgfsX5,
p.Ile214PhefsX4,  p.Lys647PhefsX4)  of  the  open  reading
frame. The analysis of the splice site mutation (c.719–2A>G)
with  Human  Splicing  Finder  software  showed  that  the
consensus value of the wild-type splice acceptor site was
decreased by 33.5%, suggesting a partial disruption of the
normal splicing event.
Additional genetic analysis among members of the RB4,
RB5,  RB14,  and  RB37  families  revealed  four  bilateral
sporadic cases, for whom the causative mutations were absent
in the parents, suggesting that these mutations are de novo,
potentially expressed in a germinal mosaicism state in one of
the asymptomatic parents. For the RB14 family, the mutation
was also absent in the two siblings; in one, the genetic analysis
was performed on umbilical cord blood. The analysis of the
RB20 and RB21 cases belonging to the same family showed
the presence of the same causative splice site mutation (c.719–
2A>G) in the patients, which was associated with unilateral
and unifocal RB. The transmission analysis (Figure 1) of this
mutation showed that their fathers and other family members
were healthy carriers of this mutation, without any clinical
symptoms.
In addition, the genetic analysis showed eight intronic
RB1 changes not predicted to be pathogen variants (Table 2).
Of these, seven were single-base substitutions: g.39598A>G,
g.39606T>C and g.39573T>C (intron 3), g.42068G>T (intron
4), g.59643T>C (intron 7), g.73724A>G (intron 12), and g.
150191A>G (intron 19); and one deletion of seven bases in
the  intron  12  (g.73734_73740delCTGTTTT).  The  new
changes  (g.59643T>C,  g.150191A>G,  and  g.
73734_73740delCTGTTTT)  were  evaluated  with  Human
Splice Finder and were not predicted to have an impact on
splicing.
DISCUSSION
This  is  the  first  report  of  RB1  mutational  screening  in
Moroccan patients with RB. The screening of RB1 germline
mutations in 41 patients identified ten different mutations. The
global mutation detection rate was 24.39% (ten out of 41
patients) with 40% (10/25) in the heritable cases and 0%
(0/16)  in  the  sporadic  unilateral  cases.  Previous  reports
described a high heterogeneity of the detection rate ranging
from 19% to 72% (Table 3). [8,14,16,17,19,23–31]. This rate
increases  for  heritable  cases,  with  a  maximum  of  94.8%
detected by a recent study performed on 1,024 patients [19].
For sporadic unilateral cases, researchers have postulated that
about 10%–12% of cases are caused by germline mutations
[1].  In  90  sporadic  unilateral  probands  of  French  origin,
Houdayer et al. [14] found germline mutations in 5.5% of the
Molecular Vision 2011; 17:3541-3547 <http://www.molvis.org/molvis/v17/a380> © 2011 Molecular Vision
3542T
A
B
L
E
 
1
.
 
R
B
1
 
G
E
R
M
L
I
N
E
 
M
U
T
A
T
I
O
N
S
 
I
D
E
N
T
I
F
I
E
D
 
I
N
 
M
O
R
O
C
C
A
N
 
P
A
T
I
E
N
T
S
 
W
I
T
H
 
R
E
T
I
N
O
B
L
A
S
T
O
M
A
P
a
t
i
e
n
t
g
-
p
o
s
i
t
i
o
n
a
c
D
N
A
 
c
h
a
n
g
e
b
P
r
o
t
e
i
n
L
o
c
a
t
i
o
n
L
a
t
e
r
a
l
i
t
y
O
c
c
u
r
r
e
n
c
e
s
c
R
B
3
g
.
1
5
3
3
4
7
A
>
T
c
.
1
9
5
4
A
>
T
p
.
L
y
s
6
5
2
X
E
x
o
n
 
1
9
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
1
)
R
B
4
g
.
3
9
5
5
2
_
3
9
5
5
3
d
e
l
T
A
c
.
3
7
1
_
3
7
2
d
e
l
T
A
p
.
I
l
e
1
2
4
A
r
g
f
s
X
5
E
x
o
n
 
3
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
3
)
R
B
5
g
.
1
6
2
2
3
7
C
>
T
c
.
2
3
5
9
C
>
T
p
.
A
r
g
7
8
7
X
E
x
o
n
 
2
3
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
6
2
)
R
B
1
4
g
.
1
5
3
3
3
2
_
1
5
3
3
3
3
d
e
l
C
T
c
.
1
9
3
9
_
1
9
4
0
d
e
l
C
T
p
.
L
y
s
6
4
7
P
h
e
f
s
X
4
E
x
o
n
 
1
9
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
4
)
R
B
1
6
g
.
5
6
8
8
5
d
e
l
A
c
.
6
4
0
d
e
l
A
p
.
I
l
e
2
1
4
P
h
e
f
s
X
4
E
x
o
n
 
7
B
i
l
a
t
e
r
a
l
N
o
R
B
1
9
g
.
1
5
3
3
4
6
T
>
G
c
.
1
9
5
3
T
>
G
p
.
T
y
r
6
5
1
>
X
E
x
o
n
 
1
9
B
i
l
a
t
e
r
a
l
N
o
R
B
2
0
,
 
R
B
2
1
g
.
5
9
6
4
9
A
>
G
c
.
7
1
9
–
2
A
>
G
A
l
t
e
r
e
d
 
s
p
l
i
c
i
n
g
I
n
t
r
o
n
 
7
u
n
i
l
a
t
e
r
a
l
N
o
R
B
2
6
g
.
7
8
2
3
8
C
>
T
c
.
1
6
5
4
C
>
T
p
.
A
r
g
5
5
2
X
E
x
o
n
 
1
7
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
6
3
)
R
B
3
7
g
.
7
6
4
6
0
C
>
T
c
.
1
3
6
3
C
>
T
p
.
A
r
g
4
5
5
X
E
x
o
n
 
1
4
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
5
3
)
R
B
3
9
g
.
6
5
3
8
6
C
>
T
c
.
1
0
7
2
C
>
T
p
.
A
r
g
3
5
8
X
E
x
o
n
 
1
1
B
i
l
a
t
e
r
a
l
Y
e
s
 
(
6
0
)
 
 
 
 
 
 
 
 
 
 
a
p
o
s
i
t
i
o
n
 
i
n
 
R
B
1
 
g
e
n
o
m
i
c
 
s
e
q
u
e
n
c
e
 
(
G
e
n
B
a
n
k
 
a
c
c
e
s
s
i
o
n
 
n
u
m
b
e
r
 
L
1
1
9
1
0
.
1
)
 
b
N
u
c
l
e
o
t
i
d
e
 
n
u
m
b
e
r
i
n
g
 
r
e
f
l
e
c
t
s
 
c
D
N
A
 
n
u
m
b
e
r
i
n
g
 
w
i
t
h
 
+
1
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
t
o
 
t
h
e
 
A
 
o
f
 
 
 
 
 
 
 
t
h
e
 
A
T
G
 
t
r
a
n
s
l
a
t
i
o
n
 
i
n
i
t
i
a
t
i
o
n
 
c
o
d
o
n
 
i
n
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
e
q
u
e
n
c
e
 
(
N
M
_
0
0
0
3
2
1
.
2
)
.
 
c
N
u
m
b
e
r
 
o
f
 
o
c
c
u
r
r
e
n
c
e
s
 
(
i
n
 
p
a
r
e
n
t
h
e
s
i
s
)
 
i
n
 
t
h
e
 
l
i
t
e
r
a
t
u
r
e
 
b
a
s
e
d
 
o
n
 
t
h
e
 
R
B
1
 
g
e
n
e
 
 
 
 
 
 
 
d
a
t
a
b
a
s
e
 
2
0
1
1
.
Molecular Vision 2011; 17:3541-3547 <http://www.molvis.org/molvis/v17/a380> © 2011 Molecular Vision
3543cases. However, based on a small selected sample of 21 Indian
unilateral patients, mutations were detected in 23.8% of cases
[16]. In addition, on a widely selected sample of 385 unilateral
cases,  Rushlow  et  al.  [19]  found  52  (13.5%)  carriers  of
mutations  in  blood.  This  heterogeneity  of  the  mutation
detection rate could mainly be explained by the technique
diversity used and the size of the cohorts studied (Table 3).
Indeed, some techniques [18,32] such as direct sequencing or
denaturing high pressure liquid chromatography [14,16,24,
30] are known as more efficient to detect point mutations.
Others such as cytogenetic, fluorescent in situ hybridization,
and quantitative multiplex PCR techniques are more efficient
for detecting large gene rearrangements. Recently, Houdayer
et al. (2011) [33] described a new method, called multiplex
PCR/liquid chromatography, to screen for large deletions and
duplications.  The  European  Molecular  Quality  Network
(EMQN)  recommended  combining  two  or  more  different
methods to increase the sensitivity of RB1 mutation detection.
The mutation rate reported in the present study is similar to
those found by other groups using screening techniques based
on  PCR  sequencing  (Table  3)  [28,29];  however,  higher
detection rates have been reported when a combination of
approaches  was  used  [14,16,18,19].  Thus,  other  mutation
screening  technologies  sensitive  to  short  and  large
rearrangements should be used to maximize the detection rate
in our cohort. In addition to the techniques used for detection
analysis, other explanations could be provided to explain the
high rate of cases negative for RB1 mutations, especially for
patients with heritable RB. In the patients who were RB1
negative, 16 were unilateral sporadic cases, either bearing two
somatic mutations or having an RB1 mutation in a mosaic
state. In the heritable cases, consisting of one familial and 14
bilateral sporadic presentations, the absence of mutation could
be  explained  either  by  the  inactivation  of  RB1  through
mutation in non-coding regions situated outside the explored
sequences or by an epigenetic alteration, as bilateral sporadic
cases are carriers of somatic mosaicism and cannot be detected
in blood samples [16,19,27]. In addition, the large size of the
RB1 gene, the high degree of mutational heterogeneity of the
disease  (>900  RB1  mutations),  and  the  quality  of  the
Figure 1. Segregation of the c.719–2A>G splice mutation in the RB20 and RB21 families associated with unilateral retinoblastoma. The
genotype is provided for the tested members as wt/+ for heterozygous carriers and wt/wt for homozygous relatives. Half-filled symbols:
affected unilateral patients; dotted symbols: unaffected carriers.
TABLE 2. RB1 INTRONIC VARIANTS DETECTED IN MOROCCAN PATIENTS WITH RETINOBLASTOMA
g-position cDNA change Location Occurrencesb
g.39598A>G c.380+37A>G Intron 3 Yes (2)
g.39606T>C c.380+45C>T Intron 3 Yes (3)
g.39573T>C c.380+12T>C Intron 3 Yes (2)
g.42068G>T c.500+23G>T Intron 4 Yes (2)
g.59643T>Ca c.719–8T>C Intron 7 No
g.73724A>G c.1216–29A>G Intron 12 Yes (2)
g.73734_73740delCTGTTTTa c.1216–19_-13del Intron12 No
g.150191A>Ga c.1814+74A>G Intron 19 No
         aNew variants  were  tested  for  pathogenicity  by  using  the  Human  Splicing  Finder  software.  bNumber  of  occurrences  (in
      parenthesis) in the literature based on the RB1 gene database 2011.
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3545sequencing electropherograms could also have caused the
high rate of negative cases in our study.
While the frequency of mutations detected varies widely,
the pattern of mutations is very similar in various populations,
the  most  predominant  categories  being  nonsense  and
frameshift mutations (Table 3). Our result is comparable to
those reported in these studies with about 90% of mutations
detected  being  nonsense  or  frameshift.  In  addition,  the
mutational spectrum found in our cohort does not differ from
those reported previously, even if we found novel mutations,
confirming  that  the  mutations  causing  RB  have  occurred
independently  in  the  majority  of  cases  in  the  RB1   gene.
On the other hand, the penetrance and expressivity of
heritable retinoblastoma may be determined by the mutation
type in RB1. Nonsense and frameshift mutations typically
cause multifocal bilateral tumors due to the absence of the
retinoblastoma protein, whereas intronic splice mutations are
associated  with  incomplete  penetrance  and  milder
expressivity due to a residual function of the retinoblastoma
polypeptide  [7,18,24,34,35].  In  our  cohort,  all  patients
exhibiting nonsense and frameshift mutations had bilateral
multifocal tumors, while the two familial cases displaying the
splice  site  mutation  had  unilateral  unifocal  disease.  In
addition, the mutation screening of other family members for
this splicing mutation (Figure 1) detected three unaffected
carriers suggesting low expressivity and penetrance of this
mutation. Researchers have reported that the existence of low
penetrance and variable expressivity of the disease in some
families  presenting  either  bilateral  or  unilateral  affected
patients, or unaffected carriers is related to the implication of
modifier  genes  [7,20].  Recently,  Castera  et  al.  [21]
demonstrated that the MDM2 gene is the first modifier gene
for  retinoblastoma.  In  this  study,  the  genotyping  of  the
MDM2-SNP309T>G (rs2279744) polymorphism, assessed in
70 RB families (212 carriers of germline mutations and 114
relatives), revealed a significant association of the SNP309G
allele with the presence of bilateral or unilateral tumors among
mutation  carriers  reflecting  a  recessive  contribution  of
MDM2 to tumor susceptibility [21].
Finally, researchers have reported that the majority of
patients  with  bilateral  RB  have  sporadic  disease  with  no
familial transmission, which arises by de novo mutation of
RB1 either in the germline or embryo [16]. In our cohort, the
parental screening of four probands with germline mutations
indicated  that  these  cases  were  associated  with  de  novo
mutations.
In  conclusion,  in  spite  of  the  technical  difficulty  of
analysis,  screening  for  the  RB1  gene  remains  an  integral
component of managing patients with retinoblastoma. This
screening allows the prediction of risk in relatives of probands
presenting  germline  mutations,  early  management  and
detection  of  tumors  in  predisposed  individuals,  and  the
avoidance of invasive and unnecessary examinations of non-
carriers.
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